Meliora Therapeutics

Mechanism-focused Oncology Drugs

Meliora Therapeutics is developing a proprietary prediction atlas - called AnchorOmics - to elucidate drug mechanisms and their impact on cancer biology. The "unit" AnchorOmics is a proprietary "molecular fingerprint". This fingerprint captures the impact of a therapeutic agent on the transcriptome, methylome, proteome, morphological state, and more of cells. Using advanced machine learning techniques, Meliora generates each perturbation’s fingerprint and locates that fingerprint in their atlas, thus mapping an anti-cancer drug’s mechanisms of action.